Recombinant Human ITGB3 protein ,C- His Tag

Recombinant Human ITGB3 protein ,C- His Tag

>90% as determined by SDS-PAGE

<1.0 EU per μg of the protein as determined by the LAL method.

A DNA sequence encoding the human ITGB3(Met1-Asp718) was fused with the C-terminal His Tag

P05106

Mammalian cells

Homo sapiens (Human)

79.09kDa

Supplied as solution form in PBS or lyophilized from PBS .

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

GP3A，ITGB3

Pirooznia, Abdi, Beiki, Emami, Arab, Sabzevari, Soltani-Gooshkhaneh (2020) 177Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: Biological evaluation and preclinical study Bioorganic chemistry.

Non-small cell lung carcinoma (NSCLC) is among the most lethal lung cancers responsible for 80-85% of death. αvβ3 integrin receptor subtype has been identified as a lung cancer biomarker since its expression correlates with tumor progression and metastasis. The extracellular domain of the receptor forms a binding site for RGD-based sequences. Therefore, specific targeting of αvβ3 integrin receptors by these short peptides can be an excellent candidate for cancer imaging and therapy. In this research, the radiolabeling of DOTA-E(cRGDfK)2 with 177Lu was efficiently implemented. The Log P value, in vivo, in vitro, metabolic stability, cellular uptake and specific binding of the radiopeptide was determined. The tumor targeting capacity and the therapeutic potential of the radiotracer was studied in A549 tumor-bearing mice. Imaging studies at different time intervals were performed by SPECT/CT. Radiochemical purity of more than 99% and Log P of -3.878 was obtained for 177Lu-labelled peptide. Radiotracer showed favorable in vivo, in vitro and metabolic stability. The radiopeptide dissociation constant (Kd) was 15.07 nM. Radiopeptide specific binding was more than 95%. Biodistribution studies showed high accumulation of the radiopeptide in tumor and rapid excretion by urinary route. Maximum tumor uptake was at 4 h post-injection. Following administration of this radiopeptide to mice, not only tumor growth was suppressed, but significant tumor shrinkage was also observed. In conclusion, this radiopeptide can be employed for staging, follow-up imaging and as peptide receptor radionuclide therapeutic agent allowing efficient therapy for NSCLC and other cancers overexpressing αvβ3 integrin receptors.

1搜索商品：关键字搜索；分类导航搜索；产品联系：手机/微信同号：15972188750，座机：027-65279366（推荐 ！）

2产品选购：确定好产品信息与规格，向产品客服询问底价

3提交订单：向客服提交收货人信息，选择送货方式，支付方式，发票信息

4产品发货：发票随产品一起发送，耐心等待收货即可

质量保证：

所售产品均经过严格的质量检验，确保所供产品的技术指标与生产厂家的目录、说明书、质检报告上的描述一致，请放心选购。

质量与免责说明：

买方验收产品时，如发现产品短缺、不匹配、包装破损等情况，请保持产品原包装状态，并在收货七个工作日内，以书面方式向我司提出异议。逾期未提出异议视为合格。

买方保管产品时，应按照产品标签、说明书所示保管条件保存，如系保管不当导致产品质量问题，恕不受理。

买方使用产品时。如发现产品质量问题，应在使用初期提出，而非在使用完或快使用完时提出，以备我司回收产品，确认产品质量。如确属质量问题，我司负责调换或退货。发生索赔事宜，我司将在产品价格额度范围内酌情赔偿，恕不受理超出产品本身价值之部分。自收货之日起，超过三个月未反映产品问题，恕不退换。

我司所提供的产品仅限于专业人士的科学研究使用，不得用于临床诊断或者治疗，若有单位或者个人擅自改变我司产品用途，我司不承担任何责任。